Clinical Hematology International
Volume 1, Issue 1, March 2019
1. Clinical Hematology International: Why a New Journal in Hematology?
Mohamad Mohty, Arnon Nagler, Bipin Savani
Pages: 1 - 1
2. Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies
Mohamed A. Kharfan-Dabaja, Naveen Pemmaraju, Mohamad Mohty
Pages: 2 - 9
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematologic malignancy derived from precursors of plasmacytoid dendritic cells. There is no established standard therapy for BPDCN and the efficacy of conventional chemotherapy is limited, with an anticipated median overall...
3. Management of AML Beyond “3 + 7” in 2019
Pages: 10 - 18
The therapeutic paradigm for treatment of acute myeloid leukemia (AML) is rapidly changing with the advent of a new generation of drugs targeting diverse aspects of leukemogenesis. Whereas standard treatment for AML until recently consisted of a classic chemotherapy backbone, the incorporation of novel...
4. Current Status and Perspectives of Irradiation-Based Conditioning Regimens for Patients with Acute Leukemia Undergoing Hematopoietic Stem Cell Transplantation
Rashmika R. Potdar, Sorab Gupta, Sebastian Giebel, Bipin N Savani, Gabor Varadi, Arnon Nagler, Slawomir Blamek
Pages: 19 - 27
Acute myeloid leukemia and acute lymphoblastic leukemia are the most common indications for allogeneic hematopoietic stem cell transplantation. Total body irradiation (TBI) is an important part of conditioning regimens. TBI-based regimens offer advantages in sanctuary sites but are associated with significant...
5. Fecal Microbiota Transplantation for Treatment of Acute Graft-versus-Host Disease
Roni Shouval, Mika Geva, Arnon Nagler, Ilan Youngster
Pages: 28 - 35
The growing understanding of the bidirectional relationship between the gastrointestinal (GI) microbiome and the immune system has opened up new avenues for treatment of graft-versus-host disease (GVHD). Fecal microbiota transplantation (FMT) is the transfer of stool from a donor to a recipient who harbors...
6. Challenges in Conducting Studies in Chronic Graft-versus-Host Disease
Iskra Pusic, Steven Z. Pavletic
Pages: 36 - 44
The lack of standardized criteria for measuring therapeutic response has been a major obstacle to the development of therapeutic trials in chronic graft-versus-host disease (cGvHD). Nevertheless, recent advances have been made in understanding of the biology and pathophysiology of cGvHD, as well as establishing...
7. Endothelial Dysfunction in Hematopoietic Cell Transplantation
Marta Palomo, Maribel Diaz-Ricart, Enric Carreras
Pages: 45 - 51
The goal of this review is to look at the role of endothelial damage and dysfunction in the initiation and development of early complications that appear after hematopoietic cell transplantation (HCT). These early complications share overlapping clinical manifestations and the suspicion of underlying...
8. Idiopathic Aplastic Anemia: An Update
Elena E. Solomou
Pages: 52 - 57
“Bone marrow failure” encompass all the conditions and syndromes in which there are qualitative or quantitative disorders of one or more lineages (erythroid, myelomonocytic, and/or megakaryocytic). A few years ago, the pathophysiology of these syndromes was completely unknown. Today we have better knowledge...
9. Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study
Ali Bazarbachi, Myriam Labopin, Giorgia Battipaglia, Azedine Djabali, Edouard Forcade, William Arcese, Gerard Socié, Didier Blaise, Joerg Halter, Sabine Gerull, Jan J. Cornelissen, Patrice Chevallier, Johan Maertens, Nicolaas Schaap, Jean El-Cheikh, Jordi Esteve, Arnon Nagler, Mohamad Mohty
Pages: 58 - 74
Acute myeloid leukemia (AML) with FLT3-mutation carries a poor prognosis, and allogeneic stem cell transplantation (allo-SCT) is recommended at first complete remission (CR1). We assessed 462 adults (median age 50 years) with FLT3-mutated AML allografted between 2010 and 2015 from a matched related (40%),...
10. The Recurring Problem of Drug Shortages—How Do We Overcome It?
Rishabh Gupta, Ujjawal Savani, Katie Gatwood, Katie Culos
Pages: 75 - 77